General Pathology — MCQs

General Pathology Indian Medical PG Practice Questions and MCQs

Question 1181: Which of the following is NOT a cellular adaptation?

A. Hypertrophy
B. Hyperplasia
C. Necrosis (Correct Answer)
D. Metaplasia

Explanation: **Explanation:** Cellular adaptation refers to reversible changes in the size, number, phenotype, metabolic activity, or functions of cells in response to changes in their environment [1]. These changes allow the cell to survive and continue functioning under stress. **Why Necrosis is the correct answer:** **Necrosis** is not an adaptation; it is a form of **irreversible cell injury** resulting in cell death [1]. Unlike adaptations, which are reversible and protective, necrosis occurs when the limits of adaptive responses are exceeded or when the injurious stimulus is inherently lethal. It is characterized by denaturation of intracellular proteins, enzymatic digestion of the cell, and invariably involves **inflammation**. **Why the other options are incorrect:** * **Hypertrophy (A):** An increase in the **size** of cells, resulting in an increase in the size of the organ. It occurs in cells with limited capacity to divide (e.g., cardiac muscle in hypertension). * **Hyperplasia (B):** An increase in the **number** of cells in an organ or tissue. It occurs in tissues capable of replication (e.g., breast enlargement during puberty). * **Metaplasia (D):** A reversible change in which one **adult cell type** (epithelial or mesenchymal) is replaced by another adult cell type to better withstand stress (e.g., Squamous metaplasia in the respiratory tract of smokers) [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Atrophy** is the fourth major type of cellular adaptation (decrease in cell size/number) [1]. * **Dysplasia** is often confused with adaptation but is actually **disordered growth** and is considered a pre-neoplastic condition, not a true adaptation. * **Hallmark of Irreversible Injury:** Severe mitochondrial damage and profound membrane damage (plasma and lysosomal membranes). * **Metaplasia** is reversible, but if the stimulus persists, it can progress to malignant transformation [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 45-53.

Question 1182: Defective DNA repair is seen in which of the following conditions?

A. Tuberous sclerosis
B. Ataxia telangiectasia (Correct Answer)
C. Von Hippel Lindau disease
D. Neurofibromatosis 1

Explanation: **Explanation:** The correct answer is **Ataxia telangiectasia**. This condition is an autosomal recessive disorder caused by a mutation in the **ATM gene** (Ataxia Telangiectasia Mutated) located on chromosome 11. The ATM protein is a protein kinase that plays a pivotal role in sensing **double-stranded DNA breaks** and initiating repair mechanisms [2, 4] via p53 activation. Defective ATM leads to genomic instability, hypersensitivity to ionizing radiation, and an increased risk of malignancies (especially lymphomas) [2, 3]. **Why the other options are incorrect:** * **Tuberous Sclerosis (A):** Caused by mutations in *TSC1* (Hamartin) or *TSC2* (Tuberin). These genes regulate the **mTOR pathway**, which controls cell growth and proliferation, not DNA repair. * **Von Hippel-Lindau (VHL) Disease (C):** Caused by a mutation in the *VHL* gene. The VHL protein is part of a ubiquitin ligase complex that targets **Hypoxia-Inducible Factor (HIF-1α)** for degradation. It is a tumor suppressor gene involved in oxygen sensing. * **Neurofibromatosis 1 (D):** Caused by a mutation in the *NF1* gene, which encodes **Neurofibromin**. This protein acts as a GTPase-activating protein (GAP) that negatively regulates the **RAS signaling pathway**. **High-Yield Clinical Pearls for NEET-PG:** * **DNA Repair Defect Triad:** Always remember the "Big Four" DNA repair syndromes: **Ataxia Telangiectasia** (Double-strand breaks), **Xeroderma Pigmentosum** (Nucleotide Excision Repair), **Lynch Syndrome/HNPCC** (Mismatch Repair), and **Fanconi Anemia** (DNA cross-link repair) [2]. * **Ataxia Telangiectasia Clinical Triad:** Cerebellar ataxia, oculocutaneous telangiectasia, and recurrent sinopulmonary infections (due to IgA deficiency) [1]. * **Laboratory Marker:** Elevated **Alpha-fetoprotein (AFP)** levels are characteristically seen in patients with Ataxia telangiectasia after age 2. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1300-1301. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 322-323. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 226-227. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 101-102.

Question 1183: Defect in amyloid protein folding occurs in which of the following conditions?

A. Alzheimer disease (Correct Answer)
B. Creutzfeldt-Jakob disease
C. Scrapie disease
D. Bovine spongiform encephalopathy (BSE)

Explanation: **Explanation:** The core concept tested here is the distinction between **Amyloidosis** (misfolding of extracellular proteins into beta-pleated sheets) and **Prion diseases** (misfolding of the prion protein) [1]. **1. Why Alzheimer Disease is Correct:** Alzheimer disease is a classic example of localized amyloidosis [1]. It involves the proteolytic cleavage of **Amyloid Precursor Protein (APP)**, leading to the accumulation of **Aβ (Amyloid Beta) protein** [3], [4]. These misfolded proteins aggregate into extracellular **neuritic (senile) plaques**, which are characteristic of the disease pathology [4]. **2. Why the Other Options are Incorrect:** * **Options B, C, and D (CJD, Scrapie, BSE):** These are all **Transmissible Spongiform Encephalopathies (TSEs)** caused by **Prions**. While prions involve protein misfolding (conversion of normal $PrP^c$ to abnormal $PrP^{sc}$), they are biologically distinct from classic amyloidosis. Prions are infectious proteinaceous particles that lack nucleic acids and induce a "domino effect" of misfolding in host proteins. Although $PrP^{sc}$ can form amyloid-like aggregates, they are primarily classified under Prion diseases in pathology textbooks. **High-Yield Clinical Pearls for NEET-PG:** * **Staining:** Amyloid shows **Apple-green birefringence** under polarized light when stained with **Congo Red**. * **Alzheimer Markers:** Look for Aβ plaques (extracellular) and **Tau protein** neurofibrillary tangles (intracellular) [4], [5]. * **Prion Hallmark:** The characteristic histological finding in CJD/BSE is **spongiform change** (vacuolation of neurons and gray matter) without a typical inflammatory response. * **Diagnosis:** The most sensitive gold standard for systemic amyloidosis is a **fat pad biopsy** or rectal biopsy [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 264-266. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 135-136. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Manifestations Of Central And Peripheral Nervous System Disease, pp. 719-720. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Manifestations Of Central And Peripheral Nervous System Disease, pp. 720-721. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1290-1292.

Question 1184: What does cytopathology deal with?

A. Cellular changes for diagnosis of disease (Correct Answer)
B. Tissue changes for diagnosis of disease
C. Both cellular and tissue changes for diagnosis of disease
D. None of the above

Explanation: **Explanation:** **Cytopathology** is the branch of pathology that studies and diagnoses diseases at the **cellular level**. The core principle involves examining individual cells or small clusters of cells that have been shed spontaneously, exfoliated mechanically, or aspirated using a needle [1]. Unlike histopathology, which looks at the architectural arrangement of cells within a tissue, cytopathology focuses on specific cellular morphology, including nuclear features (size, chromatin pattern, nucleoli) and cytoplasmic changes [1]. **Analysis of Options:** * **Option A (Correct):** Cytopathology specifically deals with **cellular changes**. Common techniques include Fine Needle Aspiration Cytology (FNAC), Pap smears, and body fluid analysis (e.g., pleural or ascitic fluid) [1]. * **Option B (Incorrect):** The study of **tissue changes** for diagnosis is known as **Histopathology** [2]. This requires a biopsy or surgical resection to preserve the tissue architecture (the relationship between cells and the extracellular matrix) [1]. * **Option C (Incorrect):** While both are branches of Diagnostic Pathology, they are distinct disciplines. Cytopathology lacks the "architectural" context provided by tissue sections [1]. * **Option D (Incorrect):** Option A is the standard medical definition. **NEET-PG High-Yield Pearls:** * **Father of Modern Cytopathology:** George Papanicolaou (developer of the Pap smear). * **FNAC vs. Biopsy:** FNAC is faster, less invasive, and cheaper, but a biopsy remains the "Gold Standard" for definitive diagnosis as it allows for the assessment of tissue invasion (crucial for staging malignancy) [1]. * **Liquid-Based Cytology (LBC):** A modern technique used to improve the sensitivity of Pap smears by reducing obscuring factors like blood and inflammation. * **Cell Block:** A technique where cytological sediment is processed like a tissue biopsy, bridging the gap between cytology and histology. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 256-257. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 340-341.

Question 1185: What is the most reliable investigation in amyloid disease?

A. Rectal biopsy (Correct Answer)
B. Immunoglobulin assay
C. Ultrasound
D. Urine examination

Explanation: ### Explanation **Correct Answer: A. Rectal Biopsy** The diagnosis of amyloidosis depends on the histological demonstration of amyloid deposits in tissues [1]. **Rectal biopsy** is considered the most reliable and traditional screening investigation because the submucosal vessels of the rectum are frequently involved in systemic amyloidosis (both AL and AA types) [1]. It has a high diagnostic yield (approximately 75–85%) and is relatively safe. While **Abdominal Fat Pad Aspiration** is now often the preferred initial screening test due to its non-invasive nature, Rectal Biopsy remains a gold-standard "reliable" investigation in classic pathology textbooks and exams when fat pad aspiration is not listed. **Why other options are incorrect:** * **B. Immunoglobulin assay:** While serum/urine protein electrophoresis and free light chain assays are crucial for diagnosing **AL amyloidosis** (plasma cell dyscrasias), they do not confirm the presence of amyloid deposits in tissues [1]. * **C. Ultrasound:** Imaging is non-specific. It may show organomegaly (e.g., hepatomegaly or "speckled" appearance of the heart), but it cannot provide a definitive histological diagnosis [1]. * **D. Urine examination:** This may detect Bence-Jones proteins or proteinuria (nephrotic syndrome), but it is a functional assessment rather than a diagnostic one for amyloid fibrils [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Staining:** The gold standard for diagnosis is **Congo Red stain**, which shows **Apple-green birefringence** under polarized light [2]. * **Most common site for biopsy (Initial):** Fine needle aspiration of Abdominal Fat Pad. * **Most common organ involved:** Kidney (most common cause of death is renal failure). * **Most common site for biopsy (if fat pad is negative):** Rectal biopsy. * **Secondary Amyloidosis (AA):** Associated with chronic inflammation (e.g., TB, Rheumatoid Arthritis) [3]. * **Primary Amyloidosis (AL):** Associated with Multiple Myeloma [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 135-136. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 268-269. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 136-140.

Question 1186: The light brown perinuclear pigment seen on H&E staining of the cardiac muscle fibers in the grossly normal appearing heart of an 83-year-old man at autopsy is due to deposition of:

A. Hemosiderin
B. Lipochrome (Correct Answer)
C. Cholesterol metabolite
D. Anthracotic pigment

Explanation: **Explanation:** The correct answer is **Lipochrome** (also known as **Lipofuscin**). **1. Why Lipochrome is correct:** Lipofuscin is an insoluble, yellowish-brown granular pigment often referred to as the "wear-and-tear" or "aging" pigment [1]. It is composed of polymers of lipids and phospholipids complexed with protein, derived through the **lipid peroxidation of polyunsaturated lipids** of subcellular membranes. In the heart of an elderly individual, it typically accumulates in the **perinuclear** region of cardiac myocytes [1]. When extensive, it leads to a condition known as **Brown Atrophy** of the heart. **2. Why other options are incorrect:** * **Hemosiderin:** This is a golden-yellow to brown pigment derived from hemoglobin (iron) [2]. While it looks similar on H&E, it is usually associated with iron overload (hemosiderosis) or local hemorrhage and is identified using the **Prussian Blue** stain [2]. * **Cholesterol metabolite:** Cholesterol typically appears as clear, needle-like "clefts" in tissue sections (e.g., in atherosclerosis) because the lipid is dissolved during processing; it does not form brown perinuclear granules [3]. * **Anthracotic pigment:** This is an exogenous carbon pigment (coal dust) commonly seen in the lungs and hilar lymph nodes of smokers or city dwellers [4]. It appears **jet black**, not light brown. **High-Yield Pearls for NEET-PG:** * **Nature:** Lipofuscin is a sign of free radical injury and lipid peroxidation. * **Stain:** It is positive with **Sudan Black B** and **PAS** stains. * **Electron Microscopy:** Appears as electron-dense bodies (residual bodies) within lysosomes [1]. * **Clinical Context:** Most commonly seen in the heart and liver of aging or malnourished (cachectic) patients [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 75. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 75-76. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 77. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 73.

Question 1187: Which mode of Mendelian inheritance is most common among genetic diseases?

A. Autosomal dominant (Correct Answer)
B. Autosomal recessive
C. X-linked recessive
D. X-linked dominant

Explanation: **Explanation:** **Why Autosomal Dominant (AD) is correct:** In the context of Mendelian genetics, **Autosomal Dominant** disorders are the most frequently encountered in clinical practice. This is primarily because AD traits are expressed in the **heterozygous state**, meaning only one copy of the mutant allele is required for the disease to manifest [2]. These disorders often involve mutations in **structural proteins** (e.g., Collagen in Osteogenesis Imperfecta) or **regulatory proteins/receptors** (e.g., LDL receptor in Familial Hypercholesterolemia) [2]. Because they do not require the "double hit" of two recessive alleles, they appear more frequently across generations [1]. **Why the other options are incorrect:** * **Autosomal Recessive (AR):** While AR disorders constitute the largest category of *individual* metabolic/enzyme deficiency diseases [3], they are collectively less common in the general population because they require both parents to be carriers and the offspring to be homozygous [1]. * **X-linked Recessive (XLR):** These are less common as they primarily affect males (hemizygous). Females are usually asymptomatic carriers unless skewed lyonization occurs. * **X-linked Dominant:** This is the rarest mode of Mendelian inheritance. Many such conditions (e.g., Vitamin D-resistant rickets) are uncommon, and some are lethal in males. **High-Yield Clinical Pearls for NEET-PG:** * **AD Disorders:** Usually show **vertical inheritance** (seen in every generation). They often have a **delayed age of onset** (e.g., Huntington’s disease) [2]. * **AR Disorders:** Usually show **horizontal inheritance** (seen in siblings, not parents). They often involve **enzyme deficiencies** and have an early onset [1]. * **Key Concept:** If a question asks for the most common inheritance for *enzyme deficiencies*, the answer is Autosomal Recessive. If it asks for the most common *overall Mendelian mode*, it is Autosomal Dominant. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 53-58. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 148-151. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 150-151.

Question 1188: Coagulative necrosis is characteristic of which of the following?

A. Focal bacterial infections
B. Hypoxic cell death (Correct Answer)
C. Loss of tissue architecture
D. None of the above

Explanation: **Explanation:** **Coagulative necrosis** is the most common pattern of necrosis, typically resulting from sudden ischemia or **hypoxic cell death** in all solid organs except the brain [2]. 1. **Why Option B is correct:** In hypoxic injury, the lack of oxygen leads to intracellular acidosis. This acidity denatures not only structural proteins but also enzymatic proteins (proteases). Because the lysosomal enzymes are inactivated, they cannot digest the dead cells immediately. This results in the characteristic preservation of the basic **tissue architecture** and cell outlines for several days, even though the cells are dead (often described as "tombstone appearance") [3]. 2. **Why other options are incorrect:** * **Option A:** Focal bacterial or fungal infections typically lead to **Liquefactive necrosis**. In these cases, inflammatory cells (neutrophils) release potent hydrolytic enzymes that completely digest the tissue into a liquid viscous mass (pus). * **Option C:** In coagulative necrosis, the tissue architecture is **preserved**, not lost, in the initial stages [2]. Loss of architecture is a hallmark of liquefactive or caseous necrosis. **NEET-PG High-Yield Pearls:** * **Exception Rule:** Hypoxia in the **Central Nervous System (Brain)** results in liquefactive necrosis, not coagulative [1]. * **Microscopic hallmark:** Increased eosinophilia (pinkness) of the cytoplasm and loss of nuclei (pyknosis, karyorrhexis, or karyolysis) [3]. * **Clinical Example:** Myocardial Infarction (MI) is the classic example of coagulative necrosis [2]. * **Mechanism:** Denaturation of structural and enzymatic proteins [3]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 148-149. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 53-55. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 53.

Question 1189: All the following are examples of atrophy EXCEPT?

A. Skeletal muscle, following transection of its motor neuron
B. Skeletal muscles, following long-term immobilization of the broken extremity in a cast
C. Ovary following hypophysectomy
D. Endometrium following long-term administration of estrogen (Correct Answer)

Explanation: **Explanation:** Atrophy is defined as the shrinkage in the size of a cell (or organ) by the loss of cell substance. It results from decreased protein synthesis and increased protein degradation. **Why Option D is the Correct Answer:** The endometrium is a hormone-sensitive tissue. Under the influence of **estrogen**, the endometrium undergoes **hyperplasia** (increase in the number of cells) and thickening [1]. Long-term administration of estrogen would lead to endometrial hyperplasia, which is a risk factor for endometrial carcinoma [1]. Conversely, endometrial *atrophy* occurs due to a lack of estrogen (e.g., in postmenopausal women) [2]. **Analysis of Incorrect Options (Examples of Atrophy):** * **Option A (Denervation Atrophy):** Skeletal muscle health depends on trophic signals from motor neurons. Transection leads to rapid shrinkage of muscle fibers [3]. * **Option B (Disuse Atrophy):** Immobilization in a cast reduces the metabolic demands of the muscle, leading to a decrease in fiber size [4]. * **Option C (Hormonal/Endocrine Atrophy):** The ovary depends on FSH and LH from the pituitary. A hypophysectomy (removal of the pituitary) results in the loss of these trophic hormones, causing the ovaries to atrophy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Atrophy often involves **autophagy** (cell "self-eating") and the **Ubiquitin-Proteasome pathway**. * **Brown Atrophy:** Seen in the heart/liver due to the accumulation of **Lipofuscin** (wear-and-tear pigment) during chronic atrophy. * **Key Distinction:** Atrophy is a decrease in cell *size/number*, whereas hypoplasia is the *failure* of an organ to reach full size during development. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1017-1018. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1016-1017. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Manifestations Of Central And Peripheral Nervous System Disease, pp. 730-731. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 90-91.

Question 1190: Which of the following is the receptor for LDL?

A. B100 (Correct Answer)
B. B48
C. ApoA1
D. ApoAII

Explanation: **Explanation:** The correct answer is **A. B100**. Low-Density Lipoprotein (LDL) is the primary carrier of cholesterol in the blood. To enter cells, LDL must bind to specific **LDL receptors (LDLR)** located on the surface of hepatocytes and peripheral tissues [1]. The ligand on the LDL particle that facilitates this binding is **Apolipoprotein B-100** [1]. Once B100 binds to the receptor, the entire complex is internalized via clathrin-mediated endocytosis [1]. **Analysis of Incorrect Options:** * **B. B48:** This apoprotein is unique to **chylomicrons**. It is a truncated version of B100 produced in the intestine. It lacks the LDL receptor-binding domain, which is why chylomicrons are not cleared by the LDL receptor. * **C. ApoA1:** This is the major structural protein of **HDL** (High-Density Lipoprotein). It acts as an activator of the enzyme LCAT (Lecithin-cholesterol acyltransferase), essential for reverse cholesterol transport. * **D. ApoAII:** Also found primarily in **HDL**, its exact physiological role is less defined but it is involved in triglyceride metabolism and HDL stability. **High-Yield Clinical Pearls for NEET-PG:** * **Familial Hypercholesterolemia (Type IIa):** Caused by mutations in the **LDL receptor** or the **Apo B-100** ligand, leading to severely elevated LDL levels and premature atherosclerosis [1]. * **Apo E:** Known as the "Remnant Receptor" ligand; it is required for the uptake of Chylomicron remnants and VLDL remnants (IDL) by the liver. * **Apo C-II:** Acts as a cofactor for **Lipoprotein Lipase (LPL)**; deficiency leads to Type I Hyperlipoproteinemia (Hyperchylomicronemia). * **Friedewald Formula:** LDL = Total Cholesterol – HDL – (Triglycerides/5). (Note: Not valid if TG >400 mg/dL). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 156-159.

Practice by Chapter

Cell Injury and Cell Death

Practice Questions

Adaptations of Cellular Growth

Practice Questions

Accumulations and Deposits

Practice Questions

Acute and Chronic Inflammation

Practice Questions

Tissue Repair and Wound Healing

Practice Questions

Hemodynamic Disorders

Practice Questions

Genetic Disorders

Practice Questions

Environmental Pathology

Practice Questions

Nutritional Diseases

Practice Questions

Molecular Basis of Disease

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free